N-cyclopentyl-6-[2-(4-fluorophenyl)-7-methylsulfanylpyrazolo[1,5-a]pyridin-3-yl]pyrimidin-4-amine | 437612-79-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-cyclopentyl-6-[2-(4-fluorophenyl)-7-methylsulfanylpyrazolo[1,5-a]pyridin-3-yl]pyrimidin-4-amine
• CAS: 437612-79-8
• 化学式: C₂₃H₂₂FN₅S
• 分子量: 419.526
• InChiKey: KLRJIYIAXBHQAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  80.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-cyclopentyl-6-[2-(4-fluorophenyl)-7-methylsulfanylpyrazolo[1,5-a]pyridin-3-yl]pyrimidin-4-amine 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 生成 N-cyclopentyl-3-[6-(cyclopentylamino)pyrimidin-4-yl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-amine
  参考文献：
  名称：

  Pyrazolo[1,5-a]pyridine antiherpetics: Effects of the C3 substituent on antiviral activity

  摘要：

  A recently disclosed series of pyrazolo[1,5-a]pyridine inhibitors of herpes virus replication has been closely examined herein for effects of the C3 substituent on antiviral activity. Significant changes in activity are observed by alterations of the hetero-atom basicity and orientation of the group at C3. These results in combination with previous studies have served to further elaborate the minimal pharmacophore required for potency of this novel series of antiviral agents. During the course of these studies, several novel synthetic approaches were developed and are described. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.02.058
• 作为产物：
  描述：

  N-cyclopentyl-6-iodopyrimidin-4-amine 在 bis-triphenylphosphine-palladium(II) chloride copper(l) iodide 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 生成 N-cyclopentyl-6-[2-(4-fluorophenyl)-7-methylsulfanylpyrazolo[1,5-a]pyridin-3-yl]pyrimidin-4-amine
  参考文献：
  名称：

  Pyrazolo[1,5-a]pyridine antiherpetics: Effects of the C3 substituent on antiviral activity

  摘要：

  A recently disclosed series of pyrazolo[1,5-a]pyridine inhibitors of herpes virus replication has been closely examined herein for effects of the C3 substituent on antiviral activity. Significant changes in activity are observed by alterations of the hetero-atom basicity and orientation of the group at C3. These results in combination with previous studies have served to further elaborate the minimal pharmacophore required for potency of this novel series of antiviral agents. During the course of these studies, several novel synthetic approaches were developed and are described. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.02.058

文献信息

• Use of pyrazolopyridines as therapeutic compounds
  申请人：Boyd F Leslie

  公开号：US20050107400A1

  公开（公告）日：2005-05-19

  The present invention provides methods for the treatment or prophylaxis of viral infections such as herpes viral infections.

  本发明提供了治疗或预防病毒感染，例如疱疹病毒感染的方法。
• Pyrazolopyridines, process for their preparation and use as therapeutic compounds
  申请人：Alberti John Michael

  公开号：US20060058319A1

  公开（公告）日：2006-03-16

  The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

  本发明提供了式(I)的化合物：其中所有变量如本文所定义，包含这些化合物的制药组合物，制备这些化合物的过程以及它们作为制药剂的用途。
• Pyralopyridines, process for their preparation and use as therapeutic compounds
  申请人：Alberti John Michael

  公开号：US20050059677A1

  公开（公告）日：2005-03-17

  The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

  本发明提供了式(I)的化合物：其中所有变量如本文所定义，包含它们的药物组合物，制备它们的方法以及它们作为药物剂量的用途。
• Pyrazolopyridinyl pyridine
  申请人：Boyd F. Leslie

  公开号：US20070287721A1

  公开（公告）日：2007-12-13

  The present invention provides compounds of formula (I): pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

  本发明提供公式（I）的化合物：包含它们的药物组合物，制备它们的过程以及它们作为药物制剂的用途。
• PYRAZOLOPYRIDINE DERIVATIVES
  申请人：GLAXO GROUP LIMITED

  公开号：EP1377573B1

  公开（公告）日：2005-07-27